"The price of greatness is responsibility." Sir Winston Churchill


Search the IBPA



Top Menu

Menu Sidebar

IBPA Issues
About IBPA
IBPA Constitution
FAQ-s
IBPA Events
Individual Membership
Institutional Membership
IBPA Forums / Groups
Cooperation with IBPA
Links

Publications
IBPA Careers Newsletter
Past Issues
Industry Publications
Promote Yourself within the Industry
Submit Your Article

Career Center: Employers
Job Posting
Free Resume Database
Volunteers Database

Career Center: Job Seekers
Now Hiring
Submit Resume
Career Training
Nurses Careers in Biopharm
Scholarship Programs
Internship Programs
Resume Editing & Interview Coaching
Volunteer for the Industry
Download IBPA Career Info Brochure

Industry Directories and Listings
Pharmaceutical Companies
Contract Research Organizations
Professional Associations
Recruiters and Staffing Agencies
Clinical Research Centers
Consulting Companies
Education & Training Institutions
Jobs and Resume Searching Directories
Research and Development Companies
Industry Service Providers
List Your Company

Investor's Center
Offers
Calls

Contact IBPA
USAChapter
Canadian Chapter
European Chapter
Asian Chapter

Start Your Career in Biotech with IBPA Scholarship Programs
Untitled Document



Subscribe to our "Careers in the Biopharmaceutical Industry" newsletter:

Name*:

Email*:

City:

Country:

Phone:

To unsubscribe, click here

 

 

Biochip

From Wikipedia, the free encyclopedia.

 

The development of biochips is a major thrust of the rapidly growing biotechnology industry, which encompasses a very diverse range of research efforts including genomics, proteomics, computational biology, and pharmaceuticals, among other activities. Advances in these areas are giving scientists new methods for unraveling the complex biochemical processes occurring inside cells, with the larger goal of understanding and treating human diseases. At the same time, the semiconductor industry has been steadily perfecting the science of microminiaturization. The merging of these two fields in recent years has enabled biotechnologists to begin packing their traditionally bulky sensing tools into smaller and smaller spaces, onto so-called biochips. These chips are essentially miniaturized laboratories that can perform hundreds or thousands of simultaneous biochemical reactions. Biochips enable researchers to quickly screen large numbers of biological analytes for a variety of purposes, from disease diagnosis to detection of bioterrorism agents.

Contents

[hide]

History

The development of biochips has a long history, starting with early work on the underlying sensor technology. One of the first portable, chemistry-based sensors was the glass pH electrode, invented in 1922 by Hughes (Hughes, 1922). Measurement of pH was accomplished by detecting the potential difference developed across a thin glass membrane selective to the permeation of hydrogen ions; this selectivity was achieved by exchanges between H+ and SiO sites in the glass. The basic concept of using exchange sites to create permselective membranes was used to develop other ion sensors in subsequent years. For example, a K+ sensor was produced by incorporating valinomycin into a thin membrane (Schultz, 1996). Over thirty years elapsed before the first true biosensor (i.e. a sensor utilizing biological molecules) emerged. In 1956, Leland Clark published a paper on an oxygen sensing electrode (Clark, 1956_41). This device became the basis for a glucose sensor developed in 1962 by Clark and colleague Lyons which utilized glucose oxidase molecules embedded in a dialysis membrane (Clark, 1962). The enzyme functioned in the presence of glucose to decrease the amount of oxygen available to the oxygen electrode, thereby relating oxygen levels to glucose concentration. This and similar biosensors became known as enzyme electrodes, and are still in use today.

In 1953, Watson and Crick announced their discovery of the now familiar double helix structure of DNA molecules and set the stage for genetics research that continues to the present day (Nelson, 2000). The development of sequencing techniques in 1977 by Gilbert (Maxam, 1977) and Sanger (Sanger, 1977) (working separately) enabled researchers to directly read the genetic codes that provide instructions for protein synthesis. This research showed how hybridization of complementary single oligonucleotide strands could be used as a basis for DNA sensing. Two additional developments enabled the technology used in modern DNA-based biosensors. First, in 1983 Kary Mullis invented the polymerase chain reaction (PCR) technique (Nelson, 2000), a method for amplifying DNA concentrations. This discovery made possible the detection of extremely small quantities of DNA in samples. Second, in 1986 Hood and coworkers devised a method to label DNA molecules with fluorescent tags instead of radiolabels (Smith, 1986), thus enabling hybridization experiments to be observed optically.

The rapid technological advances of the biochemistry and semiconductor fields in the 1980's led to the large scale development of biochips in the 1990's. At this time, it became clear that biochips were largely a "platform" technology which consisted of several separate, yet integrated components. Figure 1 shows the makeup of a typical biochip platform. The actual sensing component (or "chip") is just one piece of a complete analysis system. Transduction must be done to translate the actual sensing event (DNA binding, oxidation/reduction, etc.) into a format understandable by a computer (voltage, light intensity, mass, etc.), which then enables additional analysis and processing to produce a final, human-readable output. The multiple technologies needed to make a successful biochip -- from sensing chemistry, to microarraying, to signal processing -- require a true multidisciplinary approach, making the barrier to entry steep. One of the first commercial biochips was introduced by Affymetrix. Their "GeneChip" products contain thousands of individual DNA sensors for use in sensing defects, or single nucleotide polymorphisms (SNPs), in genes such as p53 (a tumor suppressor) and BRCA1 and BRCA2 (related to breast cancer) (Cheng, 2001). The chips are produced using microlithography techniques traditionally used to fabricate integrated circuits (see below).

Figure 1. Biochips are a platform that require, in addition to microarray technology, transduction and signal processing technologies to output the results of sensing experiments.
Figure 1. Biochips are a platform that require, in addition to microarray technology, transduction and signal processing technologies to output the results of sensing experiments.

Today, a large variety of biochip technologies are either in development or being commercialized. Numerous advancements continue to be made in sensing research that enable new platforms to be developed for new applications. Cancer diagnosis through DNA typing is just one market opportunity. A variety of industries currently desire the ability to simultaneously screen for a wide range of chemical and biological agents, with purposes ranging from testing public water systems for disease agents to screening airline cargo for explosives. Pharmaceutical companies wish to combinatorially screen drug candidates against target enzymes. To achieve these ends, DNA, RNA, proteins, and even living cells are being employed as sensing mediators on biochips. Numerous transduction methods can be employed including surface plasmon resonance, fluorescence, and chemiluminescence. The particular sensing and transduction techniques chosen depend on factors such as price, sensitivity, and reusability.

Microarray fabrication

The microarray -- the dense, two-dimensional grid of biosensors -- is the critical component of a biochip platform. Typically, the sensors are deposited on a flat substrate, which may either be passive (e.g. silicon or glass) or active, the latter consisting of integrated electronics or micromechanical devices that perform or assist signal transduction. Surface chemistry is used to covalently bind the sensor molecules to the substrate medium. The fabrication of microarrays is non-trivial and is a major economic and technological hurdle that may ultimately decide the success of future biochip platforms. The primary manufacturing challenge is the process of placing each sensor at a specific position (typically on a Cartesian grid) on the substrate. Various means exist to achieve the placement, but typically robotic micro-pipetting (Schena, 1995) or micro-printing (MacBeath, 1999) systems are used to place tiny spots of sensor material on the chip surface. Because each sensor is unique, only a few spots can be placed at a time. The low-throughput nature of this process results in high manufacturing costs.

Figure 2. Method for combinatorially producing single-stranded oligonucleotides using photolithography (from Pease, 1994). Each of the four nucleotides (A, G, C, and T) requires a separate lithography step.
Figure 2. Method for combinatorially producing single-stranded oligonucleotides using photolithography (from Pease, 1994). Each of the four nucleotides (A, G, C, and T) requires a separate lithography step.

Fodor and colleagues developed a unique fabrication process (later used by Affymetrix) in which a series of microlithography steps is used to combinatorially synthesize hundreds of thousands of unique, single-stranded DNA sensors on a substrate one nucleotide at a time (Fodor, 1991; Pease, 1994) (see Figure 2). As the figure shows, one lithography step is needed per base type; thus, a total of four steps is required per nucleotide level. Although this technique is very powerful in that many sensors can be created simultaneously, it is currently only feasible for creating short DNA strands (15-25 nucleotides). Reliability and cost factors limit the number of photolithography steps that can be done. Furthermore, light-directed combinatorial synthesis techniques are not currently possible for proteins or other sensing molecules.

As noted above, most microarrays consist of a Cartesian grid of sensors. This approach is used chiefly to map or "encode" the coordinate of each sensor to its function. Sensors in these arrays typically use a universal signaling technique (e.g. fluorescence), thus making coordinates their only identifying feature. These arrays must be made using a serial process (i.e. requiring multiple, sequential steps) to ensure that each sensor is placed at the correct position.

"Random" fabrication, in which the sensors are placed at arbitrary positions on the chip, is an alternative to the serial method (see Figure 3). The tedious and expensive positioning process is not required, enabling the use of parallelized self-assembly techniques. In this approach, large batches of identical sensors can be produced; sensors from each batch are then combined and assembled into an array. A non-coordinate based encoding scheme must be used to identify each sensor. As the figure shows, such a design was first demonstrated (and later commercialized by Illumina) using functionalized beads placed randomly in the wells of an etched fiber optic cable (Steemers, 2000; Michael, 1998) Each bead was uniquely encoded with a fluorescent signature. However, this encoding scheme is limited in the number of unique dye combinations that be can be used and successfully differentiated.

Figure 3. Randomly assembled microarrays use an alternative  "encoding" technique to differentiate the sensors. Sensors are made in batches from which small lots are taken to create the array. (Adapted from Gunderson, 2004.)
Figure 3. Randomly assembled microarrays use an alternative "encoding" technique to differentiate the sensors. Sensors are made in batches from which small lots are taken to create the array. (Adapted from Gunderson, 2004.)

See also

References

  • W. S. Hughes, “The potential difference between glass and electrolytes in contact with water,” J. Am. Chem. Soc. 44, pp. 2860–2866, 1922.
  • J. S. Schultz and R. F. Taylor in Handbook of Chemical and Biological Sensors, J. S. Schultz and R. F. Taylor, eds., ch. Introduction to Chemical and Biological Sensors, pp. 1–10, Institute of Physics Publishing, Philadelphia, 1996.
  • L. C. Clark, Jr., “Monitor and control of blood tissue O2 tensions,” Transactions of the American Society for Artificial Internal Organs 2, pp. 41–84, 1956.
  • L. C. Clark, Jr. and C. Lyons, “Electrode system for continuous monitoring in cardiovascular surgery,” Annals of the New York Academy of Sciences 148, pp. 133–153, 1962.
  • D. L. Nelson and M. M. Cox, Lehninger Principles of Biochemistry, Worth Publishers, New York, 2000.
  • A. M. Maxam and W. Gilbert, “A new method for sequencing DNA,” Proc. Nat. Acad. Sci. 74, pp. 560–664, 1977.
  • F. Sanger, S. Nicklen, and A. R. Coulson, “DNA sequencing with chainterminating inhibitors,” Proc. Nat. Acad. Sci. 74, pp. 5463–5467, 1977.
  • L. M. Smith, J. Z. Sanders, R. J. Kaiser, P. Hughes, C. Dodd, C. R. Connell, C. Heiner, S. B. H. Kent, and L. E. Hood, “Fluorescence detection in automated DNA sequence analysis,” Nature 321, pp. 61–67, 1986.
  • P. Fortina, D. Graves, C. Stoeckert, Jr., S. McKenzie, and S. Surrey in Biochip Technology, J. Cheng and L. J. Kricka, eds., ch. Technology Options and Applications of DNA Microarrays, pp. 185–216, Harwood Academic Publishers, Philadelphia, 2001.
  • M. Schena, D. Shalon, R. W. Davis, and P. O. Brown, “Quantitative monitoring of gene expression patterns with a complementary DNA microarray,” Science 270, pp. 467–470, 1995.
  • G. MacBeath, A. N. Koehler, and S. L. Schreiber, “Printing small molecules as microarrays and detecting protein-ligand interactions en masse,” J. Am. Chem. Soc. 121, pp. 7967–7968, 1999.
  • S. P. Fodor, J. L. Read, M. C. Pirrung, L. Stryer, A. T. Lu, and D. Solas, “Light-directed, spatially addressable parallel chemical analysis,” Science 251, pp. 767–773, 1991.
  • A. C. Pease, D. Solas, E. J. Sullivan, M. T. Cronin, C. P. Holmes, and S. P. Fodor, “Light-generated oligonucleotide arrays for rapid DNA sequence analysis,” Proc. Natl. Acad. Sci. 91, pp. 5022–5026, 1994.
  • F. J. Steemers, J. A. Ferguson, and D. R. Walt, “Screening unlabeled DNA targets with randomly-ordered fiber-optic gene arrays,” Nature Biotechnology 18, pp. 91–94, 2000.
  • K. L. Michael, L. C. Taylor, S. L. Schultz, and D. R. Walt, “Randomly ordered addressable high-density optical sensor arrays,” Analytical Chemistry 70, pp. 1242–1248, 1998.
  • K. L. Gunderson, S. Kruglyak, M. S. Graige, F. Garcia, B. G. Kermani, C. Zhao, D. Che, T. Dickinson, E. Wickham, J. Bierle, D. Doucet, M. Milewski, R. Yang, C. Siegmund, J. Haas, L. Zhou, A. Oliphant, J.-B. Fan, S. Barnard, and M. S. Chee, “Decoding randomly ordered DNA arrays,” Genome Research 14(5), pp. 870–877, 2004.
  • C. Roberts, C. S. Chen, M. Mrksich, V. Martichonok, D. E. Ingber, and G. M. Whitesides, “Using mixed self-assembled monolayers presenting RGD and (EG)3OH groups to characterize long-term attachment of bovine capillary endothelial cells to surfaces,” J. Am. Chem. Soc. 120, pp. 6548–6555, 1998.


External links




Learn More About the Biopharmaceutical Industry and Clinical Research:


Category:

Logo sidebar
  • Analytical Chemistry
  • Bioinformatics
  • Biology
  • Biochemistry
  • Biotechnology
  • Biotechnology Companies
  • Cell Imaging
  • Chemistry
  • Chemists
  • Crystallography
  • Ecology
  • Environmentalism
  • Genetic Engineering
  • Genetically Modified Organisms
  • Genetics
  • Health
  • Health Care
  • Health Sciences
  • Medical Specialities
  • Medicine
  • Molecular Genetics
  • Pharmaceutical Industry
  • Pharmacy
  • Pharmacology

  • Powered by Wikipedia, the free encyclopedia. Articles were developed by IBPA volunteers.

    Logo sidebar

    A

    B

    C

    D

    E

    F

    G

    I

    K

    L

    M

    N

    P

    Q

    R

    S

    T


    Logo sidebar


    IBPA Sponsors and Active Supporters

    http://www.payoneer.com/
    Access Clinical Trials

    Access Clinical Trials
    Access Clinical Trials


    Allied Research International
    Allied Research International

    Altaspera Global Services Inc.
    Altaspera Global Services

    Financial Planning and Personal Insurance
    For Canadian Pharmaceutical Industry Executives


    Biorole Scientific Solutions
    Biorole Scientific Solutions

    CEREPROTEC INC. Development of Novel Neuroprotective Drugs
    CEREPROTEC INC. Development of Novel Neuroprotective Drugs

    Recruitment Advertising Agencies
    Recruitment Advertising Agencies

    Cellular Technology Ltd.
    Cellular Technology Ltd.

    Clinical Trial Network
    Free Database of Clinical Investigators

    ClinQua Clinical Trials Inc.
    ClinQua Clinical Trials Inc.

    Coronis Clinical Research Organization
    Coronis Clinical Research Organization

    CPIC Latin America
    CPIC Latin America

    Espoir Bridge Recruiters
    Espoir Bridge Recruiters

    Genentech
    Genentech

    ILS SA
    Independent Research and Laboratory Solutions

    Inova Health Research
    Inova Health Research, Inc.

    Kriger Research Group International
    Kriger Research Group International

    LCCT
    LCCT

    Metrics Research
    Complete Research Solutions on a Single Platform

    Pharmalef Developments
    Pharmalef Developments

    PrimeHealth Clinical Research Organization
    PrimeHealth Clinical Research Organization

    Research & Development RA SA
    Research & Development RA SA

    Scios Inc.
    Scios Inc. - Manufacturer of Health Care Products

    Scios Inc.
    Southeast Regional Research Group LLC.

    UniMR
    UniMR Clinical Research

    YM BioSciences
    YM BioSciences

    Become IBPA Sponsor
    Post Your Logo Here

    ©2004 International Biopharmaceutical Association Inc., all rights reserved
    Privacy Policy - Terms of Use

    Google